GlassScriptPhysician profile
Scott A Stine
NPI 1457329245
$3,918.94
in general payments reported to CMS, 2019-2025
45 companies · $865 in 2025
The $865 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $542 · 2020: $273 · 2021: $392 · 2022: $175 · 2023: $696 · 2024: $976 · 2025: $865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,537.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $535.02 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $396.51 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $371.32 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $347.38 | 2019-2025 | |
| Amgen INC. | $263.02 | 2019-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $230.01 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $156.55 | 2019-2025 | Airsupra, Breztri |
| Mylan Specialty L.P. | $153.90 | 2019-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $123.62 | 2019-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $117.94 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.13 | 2019-2024 | Jardiance |
| Verona Pharma, INC. | $82.14 | 2025 | Ohtuvayre |
| Bayer Healthcare Pharmaceuticals INC. | $78.68 | 2024-2025 | |
| Braintree Laboratories, INC. | $73.08 | 2022-2025 | Sutab, Suflave |
| Novartis Pharmaceuticals Corporation | $68.54 | 2019-2025 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Stine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.